.png)
When policy collides with science, the public gets caught navigating a minefield of competing claims, partisan rhetoric, and technical language that often obscures more than it clarifies. The Trump administration's recent executive order on glyphosate has brought this tension to the forefront. On February 18, 2026, President Donald Trump invoked the Defense Production Act of 1950 to declare glyphosate and elemental phosphorus as critical to national security, directing the Secretary of Agriculture to prioritize domestic production while shielding manufacturers from certain legal liabilities (White House, 2026a). The decision has ignited fierce debate, and not just because of its political dimensions. This order sits at the intersection of decades of contested scientific evidence about whether glyphosate causes cancer.
The complexity here runs deeper than simple expert disagreement. Scientific disagreement is normal and healthy. What makes the glyphosate debate particularly thorny is that it exposes fundamental questions about how we interpret evidence, assess risk, and make decisions when certainty remains elusive. The research on glyphosate and cancer exemplifies this challenge. We have correlations, associations, and mechanistic plausibility, but the causal pathway remains contested. For practitioners, policymakers, and informed citizens trying to make sense of both the science and the politics, understanding this distinction matters enormously.
Before diving into the scientific weeds, we need to understand what the administration's order actually accomplishes. The executive order, titled "Promoting the National Defense by Ensuring an Adequate Supply of Elemental Phosphorus and Glyphosate-Based Herbicides," designates these substances as materials essential to national defense under Section 101 of the Defense Production Act (White House, 2026a). The rationale centers on elemental phosphorus, which plays a role in semiconductors, lithium-ion batteries, and various defense technologies, as well as glyphosate-based herbicides, which the order frames as critical to both military readiness and agricultural productivity. The twist? There is only one domestic producer of both substances: Bayer, the company currently fighting thousands of lawsuits alleging that its glyphosate-based product Roundup causes non-Hodgkin lymphoma.
The order delegates authority to Secretary of Agriculture Brooke Rollins to allocate resources, prioritize production contracts, and issue whatever regulations are necessary to ensure adequate supply. More controversially, the order invokes Section 707 of the Defense Production Act, which provides immunity from liability for companies complying with federal directives (White House, 2026a). Critics argue this provision effectively shields Bayer from accountability in ongoing litigation, including a case headed for Supreme Court oral arguments on April 27, 2026 (Monsanto v. Durnell).
The administration's justification emphasizes agricultural economics. Glyphosate-based herbicides are described as "the most widely used crop protection tools in United States agriculture," enabling farmers to "maintain high yields and low production costs" (White House, 2026b). The order contends that "there is no direct one-for-one chemical alternative to glyphosate-based herbicides" and that restricted access would "critically jeopardize agricultural productivity" (White House, 2026a). From a national security angle, the administration points to insufficient domestic production capacity. The United States imports more than 6 million kilograms of elemental phosphorus annually, and the order argues that reliance on foreign sources creates strategic vulnerability (White House, 2026b).
This framing positions glyphosate as an economic and security imperative rather than a public health concern. The timing raises eyebrows, though. The order arrived just as Bayer proposed a $7.25 billion settlement for existing and future non-Hodgkin lymphoma claims, and just weeks before the EPA faces a court-mandated 2026 deadline to complete a glyphosate safety reevaluation. The confluence of these events has fueled suspicions that the policy serves corporate interests at least as much as national ones.
The scientific literature on glyphosate and cancer risk is extensive, methodologically diverse, and deeply contested. Making sense of this evidence requires distinguishing between different types of studies and recognizing that animal bioassays, epidemiological cohorts, and mechanistic investigations each contribute something different to our understanding of risk. If you want to build the skills to evaluate these types of studies yourself, read our guide on Navigating Scientific Literature in Health and Fitness. More critically, it requires wrestling with the difference between correlation, association, and causation. These terms get conflated in public discourse, but they represent conceptually distinct ideas in scientific reasoning.
The most comprehensive recent animal study on glyphosate comes from the Global Glyphosate Study, a multi-institutional investigation led by the Ramazzini Institute and published in Environmental Health in January 2025 (Mandrioli et al., 2025). This two-year carcinogenicity study administered glyphosate and two commercial formulations (Roundup Bioflow, used in the European Union, and RangerPro, used in the United States) to Sprague-Dawley rats beginning at gestational day 6 and continuing through 104 weeks of age. The doses tested were 0.5, 5, and 50 mg/kg body weight per day. These levels correspond to the European Union's Acceptable Daily Intake and No Observed Adverse Effect Level, thresholds that regulatory agencies use to define "safe" exposure.
The findings were striking. Across all three treatment groups, researchers observed statistically significant dose-related increases in benign and malignant tumors at multiple anatomic sites: hematopoietic tissues (leukemia), liver, thyroid, nervous system, ovary, mammary gland, kidney, urinary bladder, and bone (Mandrioli et al., 2025). Many of these tumors are rare in Sprague-Dawley rats, with background incidences below 1% in historical controls. Perhaps most alarming was the early onset of disease. Forty percent of leukemia deaths in treated groups occurred before 52 weeks of age, comparable to premature mortality in humans under age 40 (George Mason University College of Public Health, 2025).
From a mechanistic perspective, these findings align with the International Agency for Research on Cancer's 2015 classification of glyphosate as "probably carcinogenic to humans" (Group 2A). That designation was based on sufficient evidence of carcinogenicity in experimental animals and limited evidence in humans (IARC, 2015). The IARC review also identified strong mechanistic evidence, including genotoxicity, oxidative stress, and chronic inflammation, all of which are hallmarks of carcinogenic processes. The Global Glyphosate Study results provide what the authors call "robust evidence supporting IARC's conclusion" and demonstrate that effects occur at exposure levels deemed safe by regulatory authorities (Mandrioli et al., 2025, p. 1).
That said, animal studies do not directly translate to human risk. Rats metabolize glyphosate differently than humans do, and the relevance of high-dose rodent exposures to real-world human exposures remains an open question. This is where epidemiology becomes essential. We need to see what happens in human populations actually exposed to glyphosate under real-world conditions.
The epidemiological literature presents a more nuanced picture. Two studies illustrate this complexity particularly well.
The Agricultural Health Study is the largest and most frequently cited epidemiological investigation of glyphosate and cancer risk (Andreotti et al., 2018). This prospective cohort followed 54,251 licensed pesticide applicators from Iowa and North Carolina through 2012–2013, capturing 5,779 incident cancer cases. The study found no statistically significant association between glyphosate use and cancer at any site, including non-Hodgkin lymphoma and its subtypes. This finding carries weight because non-Hodgkin lymphoma is the malignancy most consistently linked to glyphosate exposure in other studies and was central to IARC's classification.
However, the Agricultural Health Study did identify a potential signal for acute myeloid leukemia. Among applicators in the highest exposure quartile, there was a more than twofold increased risk of AML compared to never-users (RR = 2.44, 95% CI = 0.94 to 6.32), though this association did not reach statistical significance (Andreotti et al., 2018). When researchers applied exposure lags to account for latency periods between exposure and disease onset, the association strengthened. With a 20-year lag, the risk estimate for the highest tertile reached statistical significance (RR = 2.04, 95% CI = 1.05 to 3.97, Ptrend = .04), suggesting that prolonged, high-level exposure may increase AML risk. The authors cautiously concluded that "there was some evidence of increased risk of AML among the highest exposed group that requires confirmation" (Andreotti et al., 2018, p. 509).
This finding matters not because it proves causation, which it does not, but because it demonstrates dose-response, a pattern where higher exposures correlate with greater risk. Dose-response relationships are a key criterion in causal inference frameworks, though they are not sufficient on their own. The Agricultural Health Study also has methodological limitations. It relies on self-reported pesticide use, which introduces measurement error, and it primarily captures occupational exposures in a healthy, predominantly male workforce. This limits how well we can generalize the findings to the broader population, including children and individuals with chronic health conditions.
A second epidemiological study, published in Carcinogenesis in 2024, examined urinary glyphosate levels and all-cause mortality in a nationally representative sample of U.S. adults from the 2013–2016 National Health and Nutrition Examination Survey (Untalan et al., 2024). Among 2,910 participants, the mean urinary glyphosate concentration was 0.53 ng/mL, with about a quarter of samples at or below the detection limit. When researchers linked these data to mortality records through 2019, higher glyphosate levels showed a borderline association with increased mortality (adjusted hazard ratio = 1.33, 95% CI = 0.99–1.77, P = 0.06). When other pesticide exposures were excluded from the statistical model, the association reached statistical significance (Untalan et al., 2024).
This study adds value because it captures population-level exposure rather than just occupational use. It also relies on biomarkers (urinary glyphosate) rather than self-report, which reduces measurement error. However, it examines all-cause mortality rather than cancer-specific outcomes, and the follow-up period is relatively short. The association is also correlational. Higher urinary glyphosate associates with increased mortality, but we cannot infer that glyphosate caused those deaths. This is a common trap in health analysis known as the Post Hoc Ergo Propter Hoc fallacy, where sequential events are assumed to be causal. Residual confounding, where unmeasured factors influence both glyphosate exposure and mortality risk, remains a real possibility.
This is where precise language becomes critical. In epidemiology, a correlation describes a statistical relationship between two variables. For example, higher glyphosate exposure correlates with increased mortality. An association is a more formal term indicating that the relationship persists after adjusting for potential confounders, but it still does not imply causation. Causation requires satisfying a more stringent set of criteria, often guided by frameworks such as the Bradford Hill criteria. These include temporal sequence (exposure precedes disease), dose-response, biological plausibility, consistency across studies, and experimental evidence (Hill, 1965).
The current evidence on glyphosate satisfies some but not all of these criteria. Animal studies provide biological plausibility and experimental evidence of carcinogenicity at doses considered safe for humans. Epidemiological studies show associations, most notably for acute myeloid leukemia in high-exposure groups, but these associations are not consistent across all studies or cancer types. The IARC classification reflects this ambiguity. "Probably carcinogenic" (Group 2A) indicates that causation is plausible but not definitively established (IARC, 2015).
What does this mean in practical terms? We have reason for concern, but not certainty. The precautionary principle, the idea that we should err on the side of protecting public health when faced with uncertain but potentially serious risks, would argue for reducing glyphosate exposure. This is especially true for vulnerable populations such as pregnant women, children, and agricultural workers. At the same time, policymakers must weigh the economic and agricultural costs of restricting glyphosate use, particularly when readily available, equally effective alternatives do not exist.
This is the challenge the EPA faces as it approaches its 2026 deadline to complete a glyphosate safety reevaluation. An internal EPA transition document from October 2024 acknowledges that the agency "intends to revisit and better explain its evaluation of the carcinogenic potential of glyphosate" in response to a court-ordered remand (U.S. Environmental Protection Agency, 2024, p. 2). The document notes that the agency's previous conclusions were either "incomplete, unclear, incorrect or cannot be used as support for a future decision" (U.S. Environmental Protection Agency, 2024, p. 2). This admission underscores the scientific uncertainty and the ongoing debate even within regulatory agencies.
The Trump administration's executive order has ignited fierce political opposition, particularly from supporters of the "Make America Healthy Again" movement. This health-focused coalition helped propel Robert F. Kennedy Jr. to his position as Secretary of Health and Human Services. Kennedy previously represented plaintiffs in glyphosate litigation and has been a vocal critic of the herbicide. His statement supporting the executive order argued that the U.S. agricultural system depends heavily on pesticides and herbicides, and that abrupt elimination would cause food prices to surge and farm losses to mount (White House, 2026b). Many MAHA supporters perceived this stance as a betrayal, with prominent activists describing the order as "a direct assault on MAHA" and "a gift to pesticide and chemical industry lobbies at the expense of human health" (George Mason University College of Public Health, 2025).
From a public health standpoint, the order raises several concerns. First, by invoking the Defense Production Act and granting liability immunity, it may insulate manufacturers from legal accountability precisely when scientific evidence is accumulating. Second, it prioritizes agricultural productivity and national security over precautionary health protections, even as the EPA prepares to reevaluate glyphosate's safety. Third, it sends a signal to regulatory agencies that economic and strategic considerations may outweigh health concerns, potentially influencing the EPA's forthcoming decision.
At the same time, the genuine agricultural and economic stakes deserve acknowledgment. Glyphosate is used on more than 280 million acres of U.S. cropland annually, and many farmers rely on it for cost-effective weed control (White House, 2026a). The absence of direct one-for-one chemical alternatives means that restricting glyphosate could force farmers to adopt more labor-intensive or expensive methods, with downstream effects on food prices and farm viability. These concerns are not trivial, and any policy response must grapple with trade-offs between public health, economic stability, and agricultural productivity. For public health departments navigating these complex environmental health challenges, accurate education is the first line of defense. Learn how our Public Health Education Solutions can help you deploy scalable health literacy programs in your community.
For health practitioners and public health professionals, the glyphosate debate underscores the importance of risk communication when facing scientific uncertainty. Patients and clients may ask about glyphosate exposure, particularly if they live in agricultural areas, work with herbicides, or have children. What should practitioners tell them?
Start by acknowledging the uncertainty. The evidence suggests an association between high-level glyphosate exposure and certain cancers, particularly acute myeloid leukemia, but causation is not established. For individuals with occupational exposure such as farmers, landscapers, and groundskeepers, recommend personal protective equipment, adherence to label instructions, and minimizing direct contact. For the general population, exposure occurs primarily through food residues and environmental drift, which are typically much lower than occupational exposures. Choosing organic produce, which prohibits synthetic pesticide use, can reduce dietary exposure, though the absolute risk reduction is difficult to quantify. While reducing exposure is key, avoid falling for expensive "detox" products that claim to scrub these chemicals from your system; instead, focus on supporting your body’s natural filtration systems as detailed in our article on Metabolic Health and Detox Myths.
For policymakers and regulators, the challenge involves balancing precaution with pragmatism. The EPA's forthcoming reevaluation should be guided by the best available science, free from political interference. If the evidence supports restrictions, such as prohibiting use near schools, playgrounds, or residential areas, or lowering permissible residue levels on food, those restrictions should be implemented. Simultaneously, policymakers should invest in research and development of effective, lower-risk alternatives to glyphosate, ensuring that farmers have viable options if restrictions are imposed.
For the general public, the glyphosate controversy serves as a reminder that science is a process rather than a verdict. The existence of conflicting studies does not mean that "no one knows" or that all perspectives are equally valid. Instead, it reflects the iterative nature of scientific inquiry. Hypotheses are tested, refined, and retested as new data emerge. In the case of glyphosate, the weight of evidence leans toward concern. Animal studies show carcinogenicity at regulatory-approved doses, and epidemiological studies show associations in high-exposure groups. But definitive proof of harm in humans at typical exposure levels remains elusive.
This does not mean the public should be complacent. It means we should demand transparency, rigorous science, and policies that prioritize health over corporate profit. The Trump administration's executive order may serve economic and strategic interests, but it does not resolve the underlying scientific questions about glyphosate's safety. Those questions remain urgent, and they require answers grounded in evidence rather than ideology.
The glyphosate debate exemplifies a broader challenge at the intersection of science, policy, and public health. How do we make decisions when the evidence is incomplete, the stakes are high, and competing interests pull in different directions? The Trump administration's executive order prioritizes agricultural productivity and national security, framing glyphosate as indispensable to American economic and military strength. Yet the scientific evidence, particularly the recent Global Glyphosate Study and emerging signals from epidemiological research, suggests that this framing may be incomplete.
Here is what we know. Glyphosate causes cancer in laboratory animals at doses regulators consider safe. In humans, high-level exposures are associated with increased risk of certain cancers, particularly acute myeloid leukemia, though causation is not established. Population-level exposure, measured through urinary biomarkers, is associated with increased mortality, though the mechanism and specificity of this association remain unclear. The EPA is preparing to reevaluate glyphosate's safety in 2026, even as political and economic pressures mount.
For practitioners, the path forward involves communicating risk with nuance, acknowledging both what we know and what we do not. For policymakers, it involves prioritizing public health while investing in alternatives that preserve agricultural productivity. For the public, it involves demanding accountability, transparency, and policies that reflect the best available science rather than the loudest voices or the deepest pockets.
In the end, the glyphosate controversy is about more than a single herbicide. It is about how we navigate uncertainty, how we weigh evidence, and how we balance competing values in a democratic society. The answers to those questions will shape not only the future of glyphosate policy but the broader landscape of environmental health and regulatory science for years to come.
Don't let headlines dictate your health choices. Develop the critical thinking skills to analyze health news, understand environmental risks, and build a sustainable wellness plan with the Innova Vita Health & Wellness Course.
Andreotti, G., Koutros, S., Hofmann, J. N., Sandler, D. P., Lubin, J. H., Lynch, C. F., Lerro, C. C., De Roos, A. J., Parks, C. G., Alavanja, M. C., Silverman, D. T., & Beane Freeman, L. E. (2018). Glyphosate use and cancer incidence in the Agricultural Health Study. Journal of the National Cancer Institute, 110(5), 509–516. https://doi.org/10.1093/jnci/djx233
George Mason University College of Public Health. (2025, June). International study reveals glyphosate weed killers cause multiple types of cancer. https://publichealth.gmu.edu/news/2025-06/international-study-reveals-glyphosate-weed-killers-cause-multiple-types-cancer
Hill, A. B. (1965). The environment and disease: Association or causation? Proceedings of the Royal Society of Medicine, 58(5), 295–300.
International Agency for Research on Cancer. (2015). IARC Monographs, Volume 112: Some organophosphate insecticides and herbicides. World Health Organization.
Mandrioli, D., Panzacchi, S., Manservisi, F., Bua, L., Falcioni, L., Spinaci, M., Galeati, G., Mantovani, A., Lorenzetti, S., Miglio, R., Hu, J., Chen, J., Perry, M. J., Portier, C. J., Landrigan, P. J., Antoniou, M. N., Mesnage, R., & Belpoggi, F. (2025). Carcinogenic effects of long-term exposure from prenatal life to adulthood to glyphosate and two glyphosate-based herbicides in Sprague-Dawley rats: The Global Glyphosate Study. Environmental Health, 24(1), Article 7. https://doi.org/10.1186/s12940-025-01187-2
Untalan, M., Ivic-Pavlicic, T., & Taioli, E. (2024). Urinary glyphosate levels and association with mortality in the 2013–16 National Health and Nutrition Examination Survey. Carcinogenesis, 45(3), 163–169. https://doi.org/10.1093/carcin/bgad088
U.S. Environmental Protection Agency. (2024, October 24). Glyphosate transition fact sheet [Internal document]. https://www.epa.gov/system/files/documents/2025-01/final-draft-ocspp-opp-transition-fact-sheet_glyphosate_oct-24_2024.pdf
White House. (2026a, February 18). Executive Order: Promoting the national defense by ensuring an adequate supply of elemental phosphorus and glyphosate-based herbicides. https://www.whitehouse.gov/presidential-actions/2026/02/promoting-the-national-defense-by-ensuring-an-adequate-supply-of-elemental-phosphorus-and-glyphosate-based-herbicides/
White House. (2026b, February 18). Fact sheet: President Donald J. Trump ensures an adequate supply of elemental phosphorus and glyphosate-based herbicides for national security. https://www.whitehouse.gov/fact-sheets/2026/02/fact-sheet-president-donald-j-trump-ensures-an-adequate-supply-of-elemental-phosphorus-and-glyphosate-based-herbicides-for-national-security/
